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Abstract
Alzheimer’s disease is a growing concern in the modern world. As the currently available medications are not very
promising, there is an increased need for the fabrication of newer drugs. Curcumin is a plant derived compound which has
potential activities beneficial for the treatment of Alzheimer’s disease. Anti-amyloid activity and anti-oxidant activity of
curcumin is highly beneficial for the treatment of Alzheimer’s disease. The insolubility of curcumin in water restricts its use
to a great extend, which can be overcome by the synthesis of curcumin nanoparticles. In our work, we have successfully
synthesized water-soluble PLGA coated- curcumin nanoparticles and characterized it using different techniques. As drug
targeting to diseases of cerebral origin are difficult due to the stringency of blood-brain barrier, we have coupled the
nanoparticle with Tet-1 peptide, which has the affinity to neurons and possess retrograde transportation properties. Our
results suggest that curcumin encapsulated-PLGA nanoparticles are able to destroy amyloid aggregates, exhibit anti-
oxidative property and are non-cytotoxic. The encapsulation of the curcumin in PLGA does not destroy its inherent
properties and so, the PLGA-curcumin nanoparticles can be used as a drug with multiple functions in treating Alzheimer’s
disease proving it to be a potential therapeutic tool against this dreaded disease.
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Introduction
Alzheimer’s disease (AD) is a growing concern in the modern
world. It is the most common type of dementia affecting mainly
the elderly population. With the better living conditions and
longer life span, the number of individuals affected with AD is
increasing exponentially [1,2]. Some of the major changes
occurring during AD in the brain are the accumulation of amyloid
plaques, tau protein hyperphosphorylation, mitochondrial dys-
function, oxidative and inflammatory stress. The current medica-
tions do not seem to be too optimistic in halting the disease, and
due to the multifactorial nature of the disease a number of factors
have to be taken care of while tackling AD. As a result of this
multifactorial and heterogeneous nature of the disease, compounds
with multiple properties are very good candidates for treating AD
[2–5]. Curcumin is such a versatile compound having multitude of
properties. Curcumin is the major polyphenolic compound of
Curcuma longa, a herbaceous tuberous plant endemic to South Asia.
Curcumin (M.W 368.37) is chemically diferuloymethane
(C21H20O6) and is a mixture of three major curcuminoids-
curcumin, demethoxy curcumin and bis-demethoxy curcumin
(Structure of curcumin: Figure: S1-A). It has a broad spectrum of
biological and pharmacological activities which has been utilized
since ancient times. Anti-oxidant, anti-inflammatory, anti- can-
cerous, anti-microbial, anti-parasitic, anti-cholesterol, anti- muta-
genic properties, wound healing properties, cardiovascular,
hepatic and neuronal protective activity are a few of the attributes
of curcumin [6–8]. Curcumin can modulate multiple transcription
factors, cytokines, growth factors, kinases and other enzymes.
While the intravenously or intraperitoneally administered, curcu-
min is metabolized to tetrahydrocurcumin, hexahydrocurcumin,
dihydroferulic acid and ferulic acid; the orally administered
curcumin is excreted mainly through feces in unchanged form [6].
Apart from the anti-amyloid properties [8–11] and anti-tau
hyperphosphorylation properties [12] against the two major
pathological changes in AD, curcumin is also able to regulate
the secondary changes that occur during the disease like oxidative
stress [12,13], inflammatory stress [11,14] and cholesterol
regulation [8,11] which are very beneficial while considering AD
therapy. Mohrko and co workers have found that similar to the
amyloid binding capacity [9,15], curcumin also shows affinity
towards tau-proteins [16]. As a result of an ab initio computational
study [17], it was reported that the unique charge and binding
capabilities of curcumin even facilitates its blood-brain barrier
penetration, which is very important in the case of AD. In a study
conducted by Sharma and co-workers [18], it was reported that
curcumin is able to improve membrane homeostasis, neuronal
signaling and cognitive defects after an induced traumatic brain
injury.
However, the application of curcumin is very limited due to its
hydrophobic nature and non solubility in water [19]. A way to
overcome this limitation is to prepare curcumin nanoparticles
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increase the biodistribution and bioavailability of curcumin, and
also slow down the rapid metabolism and systemic elimination
which usually occurs [7,20–22]. We have utilized Poly (lactic-co-
glycolic acid) (PLGA) for the synthesis of curcumin nanoparticles.
PLGA is a copolymer, having excellent biocompatibility and
biodegradability due to which it has been approved by the Food
and Drug Administration (FDA) for use in a number of therapeutic
applications [23]. PLGA is synthesized by random ring-opening
copolymerization of two different monomers, the cyclic dimers of
glycolic acid and lactic acid (Structure of PLGA: Figure: S1-B). It
is highly biodegradable due to its ester linkage which undergoes
hydrolysis in water forming its two original monomers. Glycolic
acid and lactic acid are the byproducts of many of the normal
metabolic pathways in the body and are metabolized and
eliminated efficiently through the Kreb’s cycle, which gives its
biocompatible and non-toxic nature [24].
The efficiency of the medication also depends on the bio-
availability at the correct location. Targeting the central nervous
system has always been a challenge due to its inaccessibility. The
stringent blood-brain barrier due to the presence of tight junctions
within the capillary endothelium severely restricts the delivery of
therapeutics to the brain [25–27] Tosi and co-workers had
successfully synthesized and targeted a PLGA nanoparticle loaded
with Loperamide and conjugated with a glycosylated heptapeptide
to the central nervous system [28]. Recently, retrograde axonal
transport has come up as a hopeful alternative to target cargos to
the brain, bypassing the blood-brain barrier [29]. With this
background, we have synthesized curcumin-PLGA nanoparticle
conjugated with a targeting moiety-Tet-1 peptide. Tet-1, a 12-
amino acid peptide, which has the binding characteristics of
tetanus toxin was identified by Boulis and coworkers through
phage-display [30]. It can interact specifically with motor neurons
and is capable of retrograde delivery in the neuronal cells. The
effectivity of the retrograde delivery and neuronal targeting has
been well studied and established by many researchers [29,30].
The amino acid sequence of Tet-1 peptide as identified by Liu et
al. is ‘HLNILSTLWKYR’ [29]. The attachment of the Tet-1
peptide to the nanoparticle was assisted by EDC/NHS coupling
reaction. EDC/NHS coupling chemistry is widely used for the
attachment of proteins or DNA to nanoparticles [31,32].
The objective of this paper is to report the conjugation of Tet-1
peptide to curcumin-PLGA nanoparticles, to study the anti-
amyloid and anti-oxidative properties of the nanoparticles and to
analyze the in vitro uptake of the nanoparticles.
Methods
1. Synthesis of PLGA-Curcumin nanoparticles
Single emulsion –solvent evaporation method, which is the best
method for encapsulating hydrophobic compounds, was used for
the synthesis of PLGA-curcumin nanoparticles [7]. Briefly,
200 mg of PLGA (50:50, MW: 7,000–17,000) was dissolved in
2 ml of ethyl acetate. 20 mg of curcumin was added to this
mixture and kept for complete dissolution for half an hour with
intermittent vortexing. 4 ml of PVA (5%w/v) in water was used as
the surfactant and the PLGA-curcumin mixture was added drop
by drop into it with intermittent vortexing at high setting. After the
complete addition of the PLGA-curcumin, the mixture was
sonicated at 40% amplitude for one minute to create a fine
emulsion. This mixture was added to 100 ml of PVA (0.3%w/v)
solution in water and rapidly stirred using a magnetic stirrer for
3 hours. PVA helps in stabilizing the emulsion and helps in
forming particles of small size and uniform size distribution. The
nanoparticles were collected by centrifugation at 6,000 rpm for
20 minutes, and washed thrice in Milli-Q water. The synthesized
nanoparticles were freeze dried and stored at 220uC till further
use. The consistencies in the synthesis parameters were checked
and the above mentioned parameters were found to be the most
efficient one. For analyses involving nanoparticles dispersed in
water, a concentration of 10 mg/ml with respect to curcumin was
used.
2. Characterization of the nanoparticles
Yield and encapsulation studies. The dry weight of the
nanoparticles was measured. Yield of the nanoparticle synthesis
was calculated [33] by the formula:
% yield~ Weight of nanoparticles obtained= ½
Weight of curcuminz ð weight of PLGA
used for the nanoparticle synthesisÞ |100
To analyze the entrapment efficiency [33] of curcumin in the
nanoparticles, the amount of curcumin in the supernatant after
each step of centrifugation during the synthesis of nanoparticles
was quantified. A standard calibration curve was plotted using
standard concentrations of curcumin dissolved in ethanol. The
spectrophotometric quantification was achieved by taking the
absorbance at 430 nm. The amount of encapsulated curcumin
and the encapsulation efficiency was calculated using the formulae:
Amount of encapsulated curcumin~
Total amount of curcumin used{the amount of
the curcumin in the supernatant
Encapsulation efficiency~ Amount of curcumin encapsulated= ð
Total amount of curcumin used for the synthesisÞ|100
Physiochemical properties of the nanoparticles. Nano-
particles dispersed in Milli Q water was used for all the analyses.
The size and morphology were characterized using electron
microscopy. Transmission Electron Microscopy (TEM) images of
the nanoparticles was taken in JEOL’s JEM 2200 FS transmission
electron microscope operating at 200 kV. The surface morphology
was studied using Scanning Electron Microscopy (SEM) and
Atomic Force Microscopy (AFM). The SEM (JEOL’s JSM 7400
SEM) was operated at 5 kV. Tapping mode of the cantilever was
used in the AFM analysis (Asylum Research’s MFP-3D-CF AFM).
The zeta potential of the particles was analyzed using the Zetasizer
of Malvern Instruments. 3D TEM tomography was also
performed to ascertain the encapsulation of curcumin inside the
PLGA nanoparticles.
The relative change in the weight of the nanoparticle with
respect to the change in temperature was studied using Thermo-
gravimetric Analysis (TGA). 15–20 mg of the dry nanoparticles
was placed in a Platinum pan and heated from 30 to 800uCa ta
heat flow rate of 10uC/min under nitrogen spurge. Attenuated
Total Reflectance - Fourier Transform Infra Red Spectroscopy
(ATR-FTIR) (Perkin Elmer Spectrum 100 FT-IR system) was
employed to study possible interaction studies and bonding pattern
between PLGA and curcumin. The Electron Spectroscopy for
Chemical Analysis (ESCA/XPS) was used to check the elemental
Curcumin-PLGA-Tet-1 Peptide in Alzheimer’s Disease
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dispersed samples were dropped on clean Silicon substrate and
dried under vacuum and the samples were analyzed in a Kratos-
Axis X-ray photoelectron spectrometer (Shimadzu, Japan)
equipped with a monochromatic Al Ka X-ray source. Pass energy
of 40 eV was used for the analyses. The elemental composition
was calculated and curve-fitting performed using Spectral Data
Processor v4.3 software.
3. Coupling of Tet-1 peptide and PLGA-curcumin
nanoparticles
For enabling the neuronal targeting of the curcumin nanopar-
ticles, we have tagged it with Tet-1 peptide.
Tet-1 peptide was custom synthesized from Operon Biotech-
nologies. Curcumin encapsulated PLGA-nanoparticles dispersed
in water was used for the attachment of Tet-1 peptide. EDC-NHS
coupling was used for the attachment of the Tet-1peptide to the
nanoparticles. Briefly, 100 ml of PLGA-coated curcumin nano-
particles was activated using 200 ml of 400 mM 1-Ethyl-3-
[3-dimethlyaminopropyl]carbodiimide hydrochloride (EDC or
EDAC) and 200 ml of 100 mM N-hydroxysulfosuccinimide
(NHS). The mixture was gently shaken for one hour at room
temperature. To this, 20 ml of Tet-1 peptide (1 mg/ml) was added,
mixed well and kept under gentle shaking for 4 hours. After the
incubation period, the nanoparticles were collected by centrifuga-
tion at 6000 rpm for 15 min and washed twice with Milli-Q water.
The resultant nanoparticles were suspended in nuclease free water
(1 ml) and used for further analyses.
4. Anti-oxidant activity of the PLGA-Curcumin
nanoparticles
Curcumin has strong anti-oxidant activity [12,13]. To analyze
the effect of PLGA coating on the curcumin nanoparticle and the
attachment of Tet-1 on the curcumin-PLGA nanoparticle, we
tested the free-radical scavenging capacity of the nanoparticles.
1,19-diphenyl-2-picrylhydrazyl (DPPH) was used as the source of
free-radicals [34]. The nanoparticles suspended in water were used
for the analysis. 4 ml of the nanoparticle was mixed with
methanolic solution of DPPH (100 mM) and kept in dark at
room temperature for 5 hours. The DPPH scavenging activity was
determined spectrophotometrically(V-650 spectrophotometer,
Jasco, Japan) at 520 nm against DPPH solution as control. The
samples were tested in triplicates. The anti-oxidant activity was
calculated as percentage of DPPH that was decreased in
comparison with the control and was calculated with the formula:
% Antioxidant activity~ Acontrol{Asample

=Acontrol|100
5. Anti-amyloid activity of PLGA-curcumin nanoparticles
The anti- amyloid activity of curcumin is a well established fact
[8–11]. We have obtained amyloid protein (1–42 fragments) from
Genscript, and dissolved it in PBS. It was left in 37uC for two
weeks to initiate aggregate formation. After the 2 week incubation
period, we have added PLGA-curcumin nanoparticles to it, and
incubated at 37uC for different intervals of time. The samples were
analyzed under SEM. The anti-amyloid activity of the Tet-1
coupled curcumin-PLGA nanoparticles were also studied similar-
ly. The Tet-1 coupled curcumin-PLGA nanoparticles and amyloid
protein aggregates were incubated at 37uC for different intervals of
time and the samples were analyzed under SEM.
6. Cytotoxicity studies
The cytotoxicity profile of the nanoparticles was studied
using two different assays- Alamar Blue and MTT assays. The
cytotoxicity profile of PLGA nanoparticles (without curcumin),
raw curcumin, PLGA-curcumin nanoparticles and PLGA-curcu-
min-Tet-1 nanoparticles were studied. Three different concentra-
tions of each sample were tested in LAG cell line (mouse fibroblast
like connective tissue). The cell lines were obtained from RIKEN
Bioresource Center, Japan. The cells were grown in DMEM+10%
FBS. Cells were seeded in the 96-well plates at a density of
5610
5cells/well and incubated at 37uCi nC O 2 incubator with 5%
CO2 for 24 hours before the addition of the nanoparticles. After
the addition of the nanoparticles, the plates were further incubated
for another 24 hours before proceeding with the particular assay.
Both the assays-Alamar Blue (Invitrogen) and MTT (Sigma) were
performed according to the manufacturer’s protocols. In Alamar
Blue assay, metabolically active cells convert the non-fluorescent
resazurin to fluorescent resorufin. The amount of fluorescence
produced is proportional to the percentage of viable cells. The
fluorescence or absorbance can be measured at 560/590 nm
(Excitation/Emission) or 570 nm respectively. In MTT assay, the
respiring cells (live cells) reduce the yellow tetrazolium salt to
purple formazan crystals by dehydrogenase enzymes secreted by
the mitochondria of metabolically active cells. Thus the amount of
formazan crystals formed is proportional to the number of viable
cells. The absorbance was taken at 560 nm against a background
absorbance taken at 690 nm (Power scan HT Microplate Reader,
Dainippon Sumitomo Pharma, Japan). Untreated cells were taken
as positive controls with 100% viability and cells without adding
the assay reagents were used as a blank. A negative control was
maintained for validation of the results and hydrogen peroxide
served as the reagent for negative control [35]. The relative cell
viability was calculated using the formula:
Relative cell viability~ Asample=Acontrol

|100
7. In vitro uptake study
Flow cytometry analysis was used to study the cellular uptake of
the Tet-1 conjugated and unconjugated curcumin-PLGA nano-
particles. The experiments were conducted in GI-1 glioma cells.
Cells were grown to attain a confluency of 10
7cells/ml.
Nanoparticles (Tet-1 attached and unattached) were added to
the cells and incubated for 4 hours. After the incubation period,
the cells were washed twice with 16Phosphate buffer saline (PBS)
to remove all the unbound nanoparticles. The cells were
trypsinized and resuspended in 500 ml1 6PBS. Cell fixation was
achieved by treating the cells with 500 ml 3% paraformaldehyde
for 20 minutes. After fixation, the cells were again washed with 16
PBS and permeabilized using 500 ml ice cold methanol and
incubated for 10 minutes. After adding 500 ml1 6PBS, cells were
again washed and finally resuspended in 16 PBS (1 ml). To
reduce cell shock, all the steps were carried out in ice. Since
curcumin-PLGA nanoparticles are auto-fluorescent in FITC
channel, no other cell staining technique was used.
8. In vitro imaging studies
The uptake of the nanoparticles were studied using confocal
laser scanning microscope (CLSM) coupled into an inverted
microscope (Olympus IX81, Japan) and the images were recorded
using a thermoelectrically cooled CCD camera (ANDOR IQ). All
the images were taken using a 1006oil immersion objective lens.
Curcumin-PLGA-Tet-1 Peptide in Alzheimer’s Disease
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growth factors to induce differentiation were seeded on glass
bottom confocal plates. After 24 hours of growth, nanoparticles
were added to the cells and incubated for 4 hours at 37uCi nC O 2
incubator with 5% CO2 for uptake by the cells. The curcumin
nanoparticles are fluorescent in the blue laser channel. To
visualize the nucleus of the cells, the cells were stained with DAPI
(49, 6-diamidino-2-phenylindole) nuclear stain, which could be
observed under the UV laser.
Results
1. Synthesis and characterization of PLGA-Curcumin
nanoparticles
Curcumin encapsulated PLGA nanoparticles were successfully
synthesized by solvent evaporation method. Consistency was
checked for different batches of the nanoparticles synthesized. (We
have observed that when the concentration of curcumin was
increased (more than 20 mg for 200 mg PLGA) during the
nanoparticle synthesis, uncoated curcumin crystals were found
among the nanoparticles on examination under SEM.) The
synthesized nanoparticles were completely soluble in water and
showed fluorescent properties under UV light. Raw curcumin
suspended in water is not soluble and do not show any
fluorescence under the UV light (Figures S2 and S3). The
synthesized nanoparticles were monodispersed and varied in size
from 150–200 nm (Figure 1A & 1B). The PLGA coating was
complete and provided a smooth surface to the nanoparticles. The
zeta potential of the nanoparticles was in the range 230 to
220 mV. The 3D TEM tomography confirmed the encapsulation
of the curcumin inside the nanoparticles. A computer generated
slice-image obtained after compiling all the images taken at
different angles show that curcumin is encapsulated inside the
nanoparticle, which is recognized from the difference in the
density of the two materials as observed in the image obtained
(Figure 1C).
Thermogravimetric analyses of PLGA nanoparticles, raw
curcumin and curcumin-encapsulated PLGA nanoparticles shows
that PLGA-curcumin nanoparticle follows the weight-loss pattern
of PLGA nanoparticles. The weight-loss in raw curcumin occurs
around 200uC, while that of the PLGA nanoparticle and PLGA-
curcumin nanoparticle occurs around after 300uC. The weight loss
in curcumin follows a gradual decrease while that of PLGA and
PLGA-curcumin nanoparticles occur more rapidly. The raw
curcumin and the curcumin loaded PLGA nanoparticles left some
residual matter after the end of thermal decomposition, while the
PLGA burnt completely without leaving behind any residual
matters (Figure 2). The result of the ATR-FTIR analyses show
that there is no chemical interaction taking place between PLGA
and curcumin (data not shown). XPS analysis helped to provide a
more qualitative and definitive verification about the composition
of the nanoparticles. It also gave a definitive proof regarding
the attachment of the Tet-1 peptide on to the surface of the
nanoparticle, which will be discussed in detail in a later section.
2. Coupling of Tet1 peptide and PLGA-Curcumin
nanoparticles
Tet-1 peptide was successfully attached to the PLGA-Curcumin
nanoparticles by EDC-NHS coupling reaction. The attachment of
Tet-1 was confirmed by N2 peak in XPS (ESCA) (Figure 3). As
XPS is one of the most versatile tools in identifying the chemical
species on a surface, we have used it for the confirmation of Tet-1
attachment to the nanoparticles. The wide spectrum obtained
shows the peaks corresponding to Carbon (284 eV), Oxygen
(532 eV) and most importantly, Nitrogen (398 eV). Nitrogen peak
is absent in PLGA-curcumin nanoparticle. Nitrogen is a
component of the peptide (Tet-1) and the amide bond formed
between the nanoparticle and peptide by NHS activation.
3. Anti-oxidant activity of the nanoparticles
The DPPH assay was used to study the free-radical scavenging
capacity of curcumin encapsulated PLGA nanoparticle in
comparison with raw curcumin. The results are plotted in the
graph (Figure 4).
Raw curcumin showed more than 80% free-radical scavenging
activity. Freshly prepared curcumin-PLGA nanoparticles had
nearly 60% free-radical scavenging activity, and the anti-oxidant
activity was decreased with the long term storage of the curcumin-
PLGA nanoparticles. Attachment of Tet-1 to the curcumin-PLGA
nanoparticles did not produce any change in its anti-oxidant
activity. Comparable anti-oxidant activity was exhibited by Tet-1
attached and Tet-1 unattached curcumin-PLGA nanoparticles. A
decrease in the anti-oxidant activity was exhibited by Tet-1
attached nanoparticles on long term storage, similar to that
exhibited by the curcumin-PLGA nanoparticles (without Tet-1).
PLGA nanoparticles (without curcumin) did not show any free-
radical scavenging activity. With lesser reaction time (30 minutes-
1 hour), there was a decrease in overall free-radical scavenging
activity. This is because; the encapsulated curcumin requires time
to leach out into the DPPH solution for the scavenging activity to
take place. The point to be noted is that the encapsulation with
PLGA does not destroy the anti-oxidant activity of curcumin.
Figure 1. Electron microscopy studies. A- TEM image of curcumin encapsulated nanopaticle; B- SEM image of curcumin-encapsulated
nanoparticle, C- 3D-TEM tomography image of curcumin encapsulated nanoparticle.
doi:10.1371/journal.pone.0032616.g001
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Anti-amyloid activity of curcumin is an interesting property
studied by many researchers. Although the exact mechanism of
curcumin activity is not known, it is an established fact that
curcumin stops the aggregation of amyloid fibrils and help in the
disaggregation of the existing plaques. We have obtained similar
results (Figure 5) when the PLGA- curcumin nanoparticles were
treated with amyloid protein aggregates. Amyloid aggregates were
formed by prolonged incubation at 37uC (Figure 5A) and treated
with the PLGA-curcumin nanoparticles to study its anti-amyloid
activity. We have observed that in due course of time, PLGA-
curcumin nanoparticles are able to slowly disaggregate the
amyloid proteins. It was observed that PLGA-curcumin nanopar-
ticles were able to attach to the amyloid aggregate surface and
decrease the size of the aggregates within 12 hours of co-
incubation (Figure 5B). After 24 hours of incubation, significant
break down in the amyloid aggregates was observed (Figure 5C)
and by 48 hours of co-incubation, the aggregates are broken down
into considerably smaller plaques (Figure 5D). We have also found
that Tet-1 attachment does not alter the anti-amyloid activity of
curcumin. Morphology of the Tet-1 attached nanoparticles and
unattached nanoparticles are similar (figure 5E and figure 1B) Tet-
1 attached curcumin-PLGA nanoparticles also exhibited anti-
amyloid activity similar to that of curcumin-PLGA nanoparticle
(without Tet-1) (figure 5F–H). It was observed that the anti-
amyloid activity of Tet-1 attached nanoparticles was slower when
compared to the Tet-1 unattached nanoparticles. By 48 hours,
complete breakdown of amyloid aggregates were observed on
treating with curcumin-PLGA nanoparticles, while after the same
duration although Tet-1 coupled nanoparticles were able to
disaggregate amyloid proteins, complete breakdown took another
24 hours (total of 72 hours). However, it has to be noted that anti-
amyloid activity remains unaltered after the attachment of Tet-1
to the curcumin-PLGA nanoparticle. No anti-amyloid effect was
observed when the amyloid protein aggregates were treated with
PLGA nanoparticles (devoid of curcumin).
5. Cytotoxicity studies
Cytotoxicity profile of the nanoparticles was studied using
Alamar Blue assay and MTT Assay. As cancer cells are sensitive
towards curcumin, we chose to use LAG, a normal mouse
fibroblast like connective tissue for the cytotoxicity analyses. Three
different concentrations of each of the test samples (PLGA
nanoparticle, raw curcumin, PLGA-curcumin nanoparticle,
PLGA-curcumin-Tet-1 nanoparticle, negative control) were used
for the studies. The respective assay reagents were added after
incubating the cells and the nanoparticles for 24 hours. The
fluorescence and absorbance readings were taken and the result
calculated. From the results obtained, it is concluded that PLGA-
curcumin nanoparticles do not possess any significant cytotoxic
effect on normal cells (Figure 6). The cells treated with the highest
concentration of nanoparticles also showed a viability of more
than 70%. Similarly, there was no significant difference in the
cytotoxicity after the attachment of the nanoparticle with Tet-1
peptide. Maintaining a negative control helped in verifying the
accuracy of the assays. It can be concluded that the nanoparticles
are highly biocompatible and do not possess any significant
toxicity in vitro.
6. In vitro uptake study
Flow cytometry experiments helped in understanding the in
vitro uptake of the targeted and non-targeted nanoparticles inside
Figure 2. TGA Analysis of PLGA nanoparticle, raw curcumin and PLGA-curcumin nanoparticle. Curcumin undergoes a gradual thermal
decomposition when compared to the rapid decomposition in PLGA and PLGA-curcumin nanoparticles.
doi:10.1371/journal.pone.0032616.g002
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study was based on the fluorescence intensity of the curcumin
nanoaprticles, which are fluorescent in the FITC channel. It was
observed that Tet-1 targeting increased the neuronal uptake of the
curcumin-PLGA nanoparticles compared to the non-targetd
curcumin-PLGA nanoparticles. Figure 7 illustrates the results
obtained after the flow cytometry analysis. It can be very clearely
observed that the uptake of the nanoparticle is increased by
multiple folds when it is targetd with Tet-1 peptide (figure 7B)
compared to the non-targeted nanoparticle (figure 7A) as per the
fluorescence data obtained. This proves that Tet-1 targeting can
be used for drug delivery to neurons with increased efficiency.
7. In vitro imaging studies
In vitro imaging studies is an important tool in studying the
targeting properties of nanoparticles. Since our curcumin
nanoparticles are auto-fluorescent, it provides a greater opportu-
nity to study its movement in vitro. Curcumin nanoparticles are
visible under the blue laser in the Confocal Laser Scanning
Microscope (CLSM). We have conducted the cell imaging studies
in GI-1 glioma cells as a model for neuronal cells. GI-1 cells were
grown in DMEM supplemented with neurotropic growth factors
to reduce division and facilitate differentiation to a small extend.
After incubation with the nanoparticles, the cells were washed with
PBS and counter stained with DAPI nuclear stain and viewed
under the CLSM. The nanoparticles are taken up inside the cells
very quickly and get distributed almost equally inside the cells
(Figure 8: A–C). After the addition of the Tet-1 targeted
nanoparticles, a greater concentration of nanoparticles is observed
around the cell soma and nucleus (Figure 8: D–F) when compared
to the non-targeted nanoparticles, confirming retrograde transport
of the nanoparticles.
Discussion
(i) Physiochemical properties of the nanoparticles
Although curcumin is a promising compound with numerous
beneficial properties, its utility is greatly restricted by its insolubility
in water. Water solubility is one of the important requirements for
an ideal drug. We have achieved water solubility by preparing
nanoparticle by encapsulating curcumin in PLGA. Apart from the
complete solubility in water, these particles also exhibit fluorescent
properties. The nanoparticles are also monodispersed in water
which also adds to its advantage. According to Lockman et al., [36],
anionic charge on the nanoparticle supports entry through the
blood-brain barrier when compared to the cationic nanoparticles.
PLGA-curcumin nanoparticles we have synthesized are slightly
anionic. The non-reactivity between PLGA and curcumin helps in
conserving the natural properties of both of these compounds.
PLGA nanoparticles are taken up by the cells mainly through the
clathrin-mediated endocytosis [37]. Cell viability studies prove that
curcumin-PLGAand Curcumin-PLGA-Tet-1 nanoparticles arenot
cytotoxic. Three different Phase I clinical trials have proven that
curcumin is safe at high doses (12 g/day) [19].
Figure 3. XPS spectra of nanoparticles. (A)- XPS spectra of PLGA-curcumin nanoparticles. (B)- XPS spectra of PLGA-Curcumin nanoparticle
attached to Tet-1 peptide. The N2 peak which identifies the presence of Tet-1 peptide can be clearly found in the spectra. The peak at 531 eV
represents Oxygen, 285 eV- Carbon and 398 eV- Nitrogen. (The peaks at 150 and 100 correspond to that of Si of the Silicon substrate- Figure S4).
doi:10.1371/journal.pone.0032616.g003
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doi:10.1371/journal.pone.0032616.g004
Figure 5. Anti-amyloid activity of PLGA-curcumin nanoparticles. A- Amyloid protein (Ab) aggregates, B- Ab and PLGA-curcumin
nanoparticles after 12 hour co-incubation, C- Ab and PLGA-curcumin nanoparticles after 24 hour co-incubation, D- Ab and PLGA-curcumin
nanoparticles after 48 hour co-incubation, E- Tet-1 conjugated PLGA-curcumin nanoparticles, F- Ab and Tet-1 attached PLGA-curcumin nanoparticles
after 12 hour co-incubation, G- Ab and Tet-1 attached PLGA-curcumin nanoparticles after 24 hour co-incubation, H- Ab and Tet-1 attached PLGA-
curcumin nanoparticles after 48 hour co-incubation. It is observed that the nanoparticles are able to attach with the amyloid aggregates and help in
disaggregation of the amyloid protein aggregates.
doi:10.1371/journal.pone.0032616.g005
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nanoparticles
The anti-oxidant property of curcumin is one of the most
important features which make its therapeutic value very high. In
AD, formation of amyloid plaques results in severe oxidative stress
in the neurons. The severe oxidative stress is also a reason for the
neuronal loss which occurs during AD. The PLGA coated
curcumin nanoparticles conserve the anti-oxidant property and
is able to scavenge the free-radical source- DPPH on reacting with
it. Although the nanoparticles are not as potent as raw curcumin, it
does exhibit comparable reactivity. Attachment of Tet-1peptide to
the nanoparticles did not affect its antioxidant activity.
We were able to reproduce the amyloid binding activity shown
by raw curcumin in our PLGA coated curcumin nanoparticles
also. The curcumin nanoparticles were able to stop the
aggregation of the amyloid plaques and disrupt the aggregates
which were already formed. Earlier it was reported by Garcia-
Alloza and coworkers [10] that in in vivo mice models, curcumin
was able to bind to amyloid plaques and dramatically clear them.
They have also reported that curcumin was able to reduce the
appearance of new plaques in these transgenic mice. They suggest
that apart from microglial activation, some other indirect
contribution is also provided by curcumin in decreasing the
amyloid burden. Similar results were published earlier by Yang et
al., [9] and Ono et al., [38]. Recently, many reports have come up
with the use of curcumin nanoformulations for the treatment of
AD. All of these reports agree on the anti-amyloid and anti-
oxidant activity of curcumin which inhibits the fibrillar and
oligomeric formations of amyloid aggregates [39]. Mourtas and
coworkers have reported the importance of structural planarity of
curcumin for anti-amyloid activity [40]. Apart from these studies,
it has also been reported that curcumin can decrease the amyloid
levels by modulating the secretory and endocytic pathways of the
amyloid-precursor protein [41].
(iii) Targeting facilitated by attachment of Tet-1 peptide
to the nanoparticles
The delivery of the drug to the right target is as important as its
activity. Targeting nanoparticles to treat diseases of cerebral origin
are very difficult due to the presence of the blood-brain barrier.
Blood-brain barrier restricts the entry of almost all particles. Due
to the unique properties of curcumin, it is able to cross the blood-
brain barrier [17]. The targeting of the nanoparticles with the Tet-
1 peptide enhances the uptake by the neuronal cells. Moreover,
there is a possibility of targeting Tet-1 conjugated nanoparticles to
the central nervous system by nasal delivery. Nasal delivery of
drugs is an alternative to invasive methods of drug administration.
Hanson and Frey [42] have reported the successful intranasal
delivery of neuroprotective peptide- NAP, in a transgenic mouse
model of AD. In another study by Gao and co-workers [25],
lectin-conjugated PEG-PLA nanoparticles have been utilized for
cerebral delivery by intranasal administration. Similar targeting
Figure 6. Cytotoxicity analyses results by Alamar Blue assay (A) and MTT assay (B) after 24 hour incubation with the nanoparticle.
Three different concentrations of the test samples were added to the cells and incubated for 24 hours before adding the respective assay reagents.
We have observed that the nanoparticles were highly biocompatible.
doi:10.1371/journal.pone.0032616.g006
Figure 7. Flow cytometry analysis of the uptake of the targeted and non-targeted nanoparticles based on the fluorescent intensity
of the nanoparticle uptake in GI-1 glioma cells. A- uptake of curcumin-PLGA nanoparticles; B- uptake of Tet-1 conjugated curcumin-PLGA
nanoparticles. Enhanced uptake of Tet-1 attached nanoparticles were observed when compared to the curcumin-PLGA nanoparticles (without Tet-1).
doi:10.1371/journal.pone.0032616.g007
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have used a glycosylated heptapeptide attached to PLGA nano-
particles for targeting central nervous system. Recently, Li and
coworkers [43] have reported the successful targeting of brain with
PEG-PLGA nanoparticles modified with a 12-mer phage-
displayed peptide (Pep TGN). They have conducted in vivo study
in mice and have found the movement of the nanoparticles across
the blood-brain barrier.
Conclusion
Treatment of Alzheimer’s disease needs to take care of the
multifactorial nature of the disease and the use of multi-functional
drugs has been identified as the need-of the hour. Apart from the
amyloid pathology, oxidative stress, inflammatory stress, tau
protein hyperphosphorylation and cholesterol homeostasis plays
important role in the development of the disease. Curcumin with
its multiple properties can be a powerful drug in treating AD. The
results of our in vitro study suggest that Tet-1 targeted PLGA
coated curcumin nanoparticles can be potential tool in treating
AD with respect to its anti-amyloid property and anti-oxidant
property, which we have reported here. Tagging the PLGA-
curcumin nanoparticle with Tet-1 neuropeptide greatly increases
its in vitro neuronal targeting efficiency. Although further con-
clusions can only be drawn only after a thorough in vivo study, the
results of this preliminary study suggest the potential role curcumin
can play in treating AD and the effect of Tet-1 peptide in neuronal
targeting of the nanoparticles. In addition to the biocompatible
nature of curcumin, the long history of its therapeutic use and low
cost of the material also adds on to the advantages and makes it a
promising candidate drug for treating AD.
Supporting Information
Figure S1 Structure of curcumin (A) and PLGA (B).
(TIF)
Figure S2 Solubility of curcumin under visible light: A-
Curcumin dissolved in water, B- Curcumin-PLGA nano-
particles in water,C- Raw curcumin dissolved in acetone.
(TIF)
Figure S3 Solubility of curcumin under UV: D- Curcu-
min dissolved in water, E- Curcumin-PLGA nanoparti-
cles in water, F- Raw curcumin dissolved in acetone.
(TIF)
Figure S4 XPS spectra of Si substrate used for the
analysis of the samples. The peak at 531 represent Oxygen
(1 s) peak, 285 represent Carbon peak (1 s) and the peaks at 151
and 99 represent the 2 s and 2p peaks of Silicon respectively.
(TIF)
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